Neuroendocrine differentiation in prostatic carcinoma

Prostate

Volumn 39, Issue 2, 1999, Pages 135-148

  Abrahamsson, Anders ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Neuroendocrine; Prognosis; Prostatic carcinoma; Therapy; Tumor progression

Indexed keywords

ANDROGEN RECEPTOR; BOMBESIN; CHROMOGRANIN A; SEROTONIN; SOMATOSTATIN;

CANCER INCIDENCE; CELL DIFFERENTIATION; HORMONAL REGULATION; HORMONE ACTION; MALIGNANT TRANSFORMATION; NEUROENDOCRINE SYSTEM; NEUROSECRETORY CELL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROTEIN EXPRESSION; REVIEW; TUMOR GROWTH;

ADENOCARCINOMA; DISEASE PROGRESSION; HUMANS; MALE; NEUROENDOCRINE TUMORS; PHENOTYPE; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 0344457271     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19990501)39:2<135::AID-PROS9>3.0.CO;2-S     Document Type: Review

References (159)

1. Murphy G, Griffiths K, Denis L, Khoury S, Chatelain C, Cockett ATK, editors. Epidemiology and natural history of prostate cancer. Proceedings of the First International Consultation on Prostate Cancer, June 20, 1996. Paris: Manchecourt Scientific Communication International; 1997;1-30.
2. Isaacs JT. Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacological intervention. Prostate [Suppl] 1990;3:1-7.
3. Chiarado A. National Cancer Institute Roundtable on Prostate Cancer: future research directions. Cancer Res 1991;51:2498-2505.
4. Davies P, Eaton C. Regulation of prostate growth. J Endocrinol 1991;131:5-17.
5. Pretl K. Zur Frage der Endokrinie der menschlichen Vorsteherdrüse. Virchows Arch [A] 1944;312:392-404.
6. Feyrter F. Über das urogenitale Helle-Zellen-System des Menschen. Mikrosk Anat Forsch 1951;57:324-326.
7. Pearse AGE. The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic, and pathologic implications of the concept. J Histochem Cytochem 1969;17:303-313.
8. Cohen R, Glezerson G, Taylor L, Grundle H, Naude J. The neuroendocrine cell population of the human prostate gland. J Urol 1993;150:365-368.
9. Battaglia S, Casali AM, Botticelli AR. Age-related distribution of endocrine cells in the human prostate: a quantitative study. Virchows Arch [A] 1994;424:165-168.
10. di Sant'Agnese PA. Neuroendocrine differentiation in carcinoma of the prostate. Cancer 1992;70:254-268.
11. Bean AJ, Zhang X, Hökfelt T. Peptide secretion: what do we know? FASEB J 1994;8:630-638.
12. Pearse AGE, Pollak JM. Neural crest origin of the endocrine polypeptide (APUD) cells of the gastrointestinal tract and pancreas. Gut 1971;12:783-788.
13. Tutton PJM, Barkla DH. Biogenic amines as regulators of the proliferative activity of normal and neoplastic intestinal epithelial cells [review]. Anticancer Res 1987;7:1-12.
14. Andrew A, Kramer B, Rawden BB. Gut and pancreatic amine precursor uptake and decarboxylation cells are not neural crest derivatives. Gastroenterology 1983;84:429-431.
15. Cussenot O, Berthon P, Cochand-Priollet B, Maitland NJ, Le Due A. Immunocytochemical comparison of cultured normal epithelial prostatic cells with prostatic tissue sections. Exp Cell Res 1994;214:83-92.
16. Merchant DJ, Clarke SM, Ives K, Harris S. Primary explant culture: an in vitro model of the human prostate. Prostate 1983; 4:523-542.
17. Bonkhoff H, Stein U, Remberger K. Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers. Hum Pathol 1994;25:42-46.
18. Bonkhoff H, Remberger K. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate 1996;28:98-106.
19. Aumüller G, Leonhardt M, Janssen M, Konrad L, Bjartell A, Abrahamsson P-A. Neurogenic origin of prostatic neuroendocrine cells. Urology 1999; in press.
20. Bang YJ, Pirnia F, Fang WG, Kang WK, Sartor O, Whitesell L, Ha MJ, Tsokos M, Sheahan MD, Nguyen P, Niklinski WT, Myers CE, Trepel JB. Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc Natl Acad Sci USA 1994;91: 5330-5334.
21. Bonkhoff H, Stein U, Remberger K. Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells. Hum Pathol 1995;26:167-170.
22. Grasso R. Sobre las celulas argentafines de la uretra y de la glandula prostatica. Arch Histol Norm Pathol 1952;5:227-270.
23. Kazzaz BA. Argentaffin and argyrophil cells in the prostate. J Pathol 1974;112:189-193.
24. Pollice L, Resta L, Simone G. APUD cells in normal and hyperplastic prostates. Ric Clin Lab 1979;9:273-278.
25. Huttner WB, Gerdes H-H, Rosa P. The granin (chromogranin/ secretogranin) family. TIBS 1991;16:27-30.
26. Russell J, Gee P, Liu SM, Angeletti RH. Inhibition of parathyroid hormone secretion by amino-terminal chromogranin peptides. Endocrinology 1994;135:337-342.
27. Schmid KD, Helpap B, Tötsch M, Kirchmair R, Dockhorn-Dworniczak B, Böcker W, Fischer-Colbrie R. Immunohistochemical localization of chromogranins A and B and secretogranin II in normal, hyperplastic and neoplastic prostate. Histopathology 1994;24:233-239.
28. di Sant'Agnese PA, de Mesy Jensen KL. Human prostatic endocrine-paracrine (APUD) cells: distributional analysis with a comparison of serotonin and neuron-specific enolase immunoreactivity and silver stains. Arch Pathol Lab Med 1985;109:607-612.
29. Abrahamsson PA, Wadström LB, Alumets J, Falkmer S, Grimelius L. Peptide-hormone- and serotonin-immunoreactive cells in normal and hyperplastic prostate glands. Pathol Res Pract 1986;181:675-683.
30. Davis NS. Determination of serotonin and 5-hydroxyindole-acetic acid in guinea pig and human prostate using HPLC. Prostate 1987;11:353-360.
31. Zifa E, Pillion G. 5-hydroxytryptamine receptors. Pharmacol Rev 1992;44:401-458.
32. Seuwen K, Pouyssegur J. Serotonin as a growth factor. Biochem Pharmacol 1990;39:985-990.
33. Lauder JM, Tamir H, Sadler TW. Serotonin and morphogenesis: sites of 5-HT uptake and -binding protein immunoreactivity in the midgestation mouse embryo. Development 1988; 102:709-720.
34. Tinajero JC, Fabbri A, Dufau ML. Regulation of corticotropin-releasing factor secretion from Leydig cells by 5-HT. Endocrinology 1992;130:1780-1787.
35. Carlei F, Polak M. Antibodies to neuron-specific enolase for the delineation of the entire diffuse neuroendocrine system in health and disease. Semin Diagn Pathol 1986;1:59-70.
36. Schmechel DE. Subunit of the glycolytic enzyme enolase: non-specific or neuron specific? Lab Invest 1985;52:239-242.
37. di Sant'Agnese PA. Calcitonin-like immunoreactive and bombesin-like immunoreactive endocrine-paracrine cells of the human prostate. Arch Pathol Lab Med 1986;110:412-415.
38. Fetissof F, Bertrand G, Guilloteau D, Dubois MP, Lanson Y, Arbeille B. Calcitonin immunoreactive cells in prostate gland and cloacal derived tissues. Virchows Arch [A] 1986;409:523-533.
39. di Sant'Agnese PA, de Mesy Jensen KL. Calcitonin, katakalcin and calcitonin gene-related peptide in the human prostate: an immunocytochemical and immunoelectron microscopic study. Arch Pathol Lab Med 1989;113:790-796.
40. Sunday M, Kaplan L, Motoyama E, Chin W, Spindel E. Biology of disease: gastrin-releasing peptide (mammalian bombesin) gene expression in health and disease. Lab Invest 1988;59:5-24.
41. di Sant'Agnese PA, de Mesy Jensen KL. Somatostatin and/or somatostatin-like immunoreactive endocrine-paracrine cells in the human prostate gland. Arch Pathol Lab Med 1984;108:693-696.
42. Fetissof F, Arbeille B, Guilloteau D, Lanson Y. Glycoprotein hormone alpha-chain-immunoreactive endocrine cells in prostate and cloacal derived tissues. Arch Pathol Lab Med 1987; 111:836-840.
43. Iwamura M, Wu G, Abrahamsson PA, di Sant'Agnese PA, Cockett ATK, Deftos LJ. Parathyroid hormone-related protein is expressed by prostatic neuroendocrine cells. Urology 1994; 43:667-674.
44. Cecio A, Cocca T, Masotti MT, La Mura E, Vittoria A. CCK-containing paraneurons in human adenomatous prostate. Biosci Rep 1993;13:251-258.
45. Abrahamsson PA, Lilja H. Partial characterization of a thyroid-stimulating hormone-like peptide in neuroendocrine cells of the human prostate gland. Prostate 1989;14:71-81.
46. Peltz SW, Jacobson A. mRNA stability: in transit. Curr Opin Cell Biol 1992;4:979-983.
47. Larsson LI. On the possible existence of multiple endocrine, paracrine and neurocrine messengers in secretory cell systems. Invest Cell Pathol 1980;3:73-85.
48. Grube D. The endocrine cells of the digestive system: amines, peptides and modes of action. Anat Embryol (Berl) 1986;175: 151-162.
49. Yamada T. Local regulatory actions of gastrointestinal peptides. In: Johnson LR, editor. Physiology of the gastrointestinal tract. New York: Raven Press; 1987. p 131-142.
50. Cutz E. Neuroendocrine cells of the lung: an overview of morphologic characteristics and development. Exp Lung Res 1982; 3:185-208.
51. Bishop A, Polak J. Gut endocrine and neural peptides. Endocr Pathol 1990;1:4-24.
52. Speirs V, Bienkowski E, Wong V, Cutz E. Paracrine effects of bombesin/gastrin related peptide and other growth factors on pulmonary neuroendocrine cells in vitro. Anat Rec 1993;236: 53-61.
53. Zachary I, Woll PJ, Rozengurt E. A role for neuropeptides in the control of cell proliferation. Dev Biol 1987;124:295-308.
54. Dalsgård CJ, Hultgårdh A, Hägerstrand A, Nilsson J. Neuropeptides as growth factors. Possible roles in human diseases. Regul Pept 1989;25:1-9.
55. Bologna M, Festuccia C, Muzi P, Biordi L, Ciomei M. Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer 1989;63:1714-1720.
56. Pinski J, Halmos G, Serially AV. Somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer in nude mice. Cancer Lett 1993;71:189-196.
57. Kadar T, Redding TW, Ben-David M, Scally AV. Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin. Proc Natl Acad Sci USA 1988;85:890-894.
58. Iwamura M, Abrahamsson P-A, Foss KA, Wu G, Cockett ATK, Deftos LJ. Parathyroid hormone-related protein: a potential autocrine growth regulator in human prostate cancer cell lines. Urology 1994;43:675-679.
59. Willey JC, Lechner JF, Harris CC. Bombesin and the C-terminal tetradecapeptide of gastrin-releasing peptide are growth factors for normal human bronchial epithelial cells. Exp Cell Res 1984;153:245-248.
60. Bonkhoff H, Wernert N, Dhom G, Remberger K. Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate. Prostate 1991;19:91-98.
61. Cockett ATK, di Sant'Agnese PA, Gopinath P, Schoen SR, Abrahamsson PA. Relationship of neuroendocrine cells of prostate and serotonin to benign prostatic hyperplasia. Urology 1993;42:512-519.
62. Sjöberg HE, Arver S, Bucht E. High concentration of immunoreactive calcitonin of prostatic origin in human semen. Acta Physiol Scand 1980;110:101-102.
63. Ulisse S, Gnessi L, Fabbri A, Jannini EA, Moretti C, Bonafacio V. Bombesin-like immunoreactivity in human seminal fluid. Regul Pept 1987;19:143.
64. Sasaki A, Yoshinaga K. Immunoreactive somatostatin in male reproductive system in humans. J Clin Endocrinol Metab 1989; 68:996-999.
65. Iwamura M, Abrahamsson PA, Schoen S, Cockett ATK, Deftos LJ. Immunoreactive parathyroid hormone-related protein is present in human seminal plasma and is of prostate origin. J Androl 1994;15:410-414.
66. Chilco PJ, Gerardi JM, Kaczmarczyk SJ, Chu S, Leopold V, Zajac JD. Calcitonin increases transcription of parathyroid hormone-related protein via cAMP. Mol Cell Endocrinol 1993;94: 1-7.
67. Prien S, Lox C, Messer R, DeLeon F. Seminal concentrations of total and ionized calcium from men with normal and decreased motility. Fertil Steril 1990;54:171-172.
68. Chung LWK, Gao C, Li W, Zhau HE. Stromal-epithelial interaction: implications for prostate tumorigenesis. Cancer Bull 1993;45:430-435.
69. Iwamura M, di Sant'Agnese PA, Wu G, Benning CM, Cockett ATK, Gershagen S. Overexpression of human epidermal growth factor receptor and c-erbB-2 by neuroendocrine cells in normal prostatic tissue. Urology 1994;43:838-843.
70. di Sant'Agnese PA. Endocrine aspects of the prostate. In: Lechago J, Gould V, editors. Bloodworth's endocrine pathology, 3rd ed. 1993.
71. Chapple CR, Crowe R, Gilpin SA, Gosling J, Burnstock G. The innervation of the human prostate gland - the changes associated with benign enlargement. J Urol 1991;146:1637-1644.
72. di Sant'Agnese PA, de Mesy Jensen KL. Endocrine-paracrine cells of the prostate and prostatic urethra: an ultrastructural study. Hum Pathol 1984;15:1034-1041.
73. Martínez-Pinero L, Dahiya R, Nunes LL, Tanagho EA, Schmidt RA. Pelvic plexus denervation in rats causes morphologic and functional changes of the prostate. J Urol 1993;150:215-218.
74. Wu G, Burzon DT, di Sant'Agnese PA, Schoen S, Deftos LJ, Gershagen S, Cockett ATK. Calcitonin receptor mRNA expression in the human prostate. Urology 1996;47:1-6.
75. di Sant'Agnese PA. Neuroendocrine differentiation in prostatic carcinoma. Hum Pathol 1992;23:287-296.
76. Abrahamsson PA, di Sant'Agnese PA. Neuroendocrine cells in the human prostate gland. J Androl 1993;14:307-309.
77. Dauge MC, Delmas V. APUD type endocrine tumor of the prostate: incidence and prognosis in association with adenocarcinma. In: Murphy GP, Khoury S, Kuss R, Chatelain C, Denis L, editors. Progress in clinical and biological medicine. New York: Alan R. Liss; 1986. p 529-531.
78. Tetu B, Ro JY, Ayala AG, Johnson DE, Logothetis CJ, Ordonez NG. Small cell carcinoma of the prostate: Part I. A clinicopathologic study of 20 cases. Cancer 1987;59:1803-1809.
79. Almagro UA, Tieu TM, Remeniuk E, Kueck R, Stumpf K. Argyrophilic, "carcinoid-like" prostatic carcinoma. Arch Pathol Lab Med 1986;110:916-919.
80. Abrahamsson PA, Wadström LB, Alumets J, Falkmer S, Grimelius L. Peptide-hormone- and serotonin-immunoreactive cells in carcinoma of the prostate. Pathol Res Pract 1987;182: 298-307.
81. Abrahamsson P-A, Falkmer S, Fält K, Grimelius L. The course of neuroendocrine differentiation in prostatic carcinomas: an immunohistochemical study testing chromogranin A as an "endocrine marker." Pathol Res Pract 1989;185:373-380.
82. Cohen RJ, Glezerson G, Haffejee Z, Afrika D. Prostatic carcinoma: histological and immunohistological factors affecting prognosis. Br J Urol 1990;66:405-410.
83. Modigliani E, Alamowitch C, Cohen R, Calmettes C, Guliana JM, Franc B, Bernard C, Chyvialle JA. The intratumoral immunoassayable somatostatin concentration is frequently elevated in medullary thyroid carcinoma. Cancer 1990;65:224-228.
84. Yamagushi A, Ishida T, Nishimura G, Kumaki T, Katoh M, K'Osaka T, Yonemura Y, Miyazaki I. Human chorionic gonadotropin in colorectal cancer and its relationship to prognosis. Br J Cancer 1989;60:382-384.
85. Hamada Y, Oishi A, Shoji T, Takada H, Yamamura M, Hioki K, Yamamoto M. Endocrine cells and prognosis in patients with colorectal carcinoma. Cancer 1992;69:2641-2646.
86. Vargas SJ, Gillespie MT, Powel GJ, Southby J, Danks JA, Mosely MJ, Martin TJ. Localization of parathyroid hormone-related protein mRNA expression in breast cancer and metastatic lesion by in situ hybridization. J Bone Miner Res 1992;7: 971-979.
87. Aprikian AG, Cordon-Cardo C, Fair WR, Reuter VE. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer 1993;71:3952-3965.
88. Paul R, Chang P, di Sant'Agnese PA, Cockett ATK, Abrahamsson P-A. Prognostic significance of neuroendocrine differentiation in human benign prostate and prostatic carcinoma. J Urol 1993;149:480.
89. de Matteis A. Tissue markers in the diagnosis and prognosis of prostatic carcinoma. Eur Urol [Suppl] 1992;21:66-70.
90. Cohen RJ, Glezerson G, Haffajee Z. Neuro-endocrine cells: a new prognostic parameter in prostate cancer. Br J Urol 1991; 68:258-262.
91. Cohen MK, Arber DA, Coffield S, Keegan GT, McClintock J, Speights VO. Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progression. Cancer 1994;74:1899-1903.
92. Noordzij MA, van der Kwast TH, van Steenbrugge GJ, Hop WJC, Scröder FH. The prognostic influence of neuroendocrine cells in prostate cancer: results of a long-term follow-up study with patients treated by radical prostatectomy. Int J Cancer 1995;62:252-258.
93. Bubendorf L, Sauter G, Moch H, Sckmid HP, Gasser TC, Jordan P, Mihatch MJ. Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 1996;178:437-441.
94. Abrahamsson PA, Cockett ATK, di Sant'Agnese PA. Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma. Prostate [Suppl] 1998;8:37-42.
95. Weinstein MH, Partin AW, Veltri RW, Epstein JI. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Hum Pathol 1996;27: 683-687.
96. McWilliam LJ, Manson C, George NJR. Neuroendocrine differentiation and prognosis in prostatic adenocarcinoma. Br J Urol 1997;80:287-290.
97. Tarle M, Rados N. Investigation on serum neuron-specific enolase in prostate cancer diagnosis and monitoring: comparative study of a multiple tumor marker assay. Prostate 1991;19:23-33.
98. Kadmon D, Thompson T, Lynch G, Scardino P. Elevated plasma chromogranin A concentrations in prostatic carcinoma. J Urol 1991;146:358-361.
99. Deftos LJ, Nakada S, Burton DW, di Sant'Agnese PA, Cockett ATK, Abrahamsson PA. Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate. Urology 1996;48:58-62.
100. Kimura N, Hoshi S, Takahashi M, Takeha S, Shizawa S, Nagura H. Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors. J Urol 1997;157:565-568.
101. Cussenot O, Villette JM, Valeri A, Cariou G, Desgrandchamps F, Cortesse A, Meria P, Teillac P, Fiet J, Le Duc A. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J Urol 1996;155:1340-1343.
102. Hoosein N, Abdul M, McCabe R, Gero A, Deftos L, Banks M, Hodges S, Finn L, Logothetis C. Clinical significance of elevation in neuroendocrine factors and interleukin-6 in metastatic prostate cancer. Urol Oncol 1995;1:246-251.
103. Angelsen A, Syversen U, Haugen OA, Stridsberg M, Mjølnerød OK, Waldum HL. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings? Prostate 1997;30:1-6.
104. Angelsen A, Syversen U, Stridsberg M, Haugen OA, Mjølnerød OK, Waldum HL. Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate. Prostate 1997; 31:110-117.
105. Cohen RJ, Glezerson G. Prostate-specific antigen and prostate-specific acid phosphatase in neuroendocrine cells of prostate cancer. Arch Pathol Lab Med 1992;116:65-66.
106. Jelbart ME, Russell PJ, Russell P, Wass J, Fullerton M, Wills EJ. Site-specific growth of the prostate xenograft line UCRY-PR-2. Prostate 1989;14:163-175.
107. Tenniswood MP, Guenette RS, Lakins J, Mooibroek M, Wong P, Welsh J-E. Active cell death in hormone-dependent tissues. Cancer Metastasis Rev 1992;11:197-220.
108. Kyprianou N, English HF, Isaacs JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 1990;50:3748-3753.
109. English HF, Kyprianou N, Isaacs JT. Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate 1989;15: 233-250.
110. Kyprianou N, Isaacs JT. Expression of transforming growth factor-β in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol 1989;3:1515-1522.
111. Sells SF, Wood DP Jr, Joshi-Barve SS, Muthukumar S, Jacob RJ, Christ SA, Humphrys S, Rangnekar VM. Commonality of the gene programs induced by the effectors of apoptosis in androgen-dependent and -independent prostate cells. Cell Growth Differ 1994;5:457-466.
112. Hockenbery DM, Zutter M, Hickey W, Moon N, Korsmeyer SJ. Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 1991;88: 6961-6965.
113. McDonnell D, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940-6944.
114. Segal NH, Cohen RJ, Haffejee Z, Savage N. BCL-2 protooncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell. Arch Pathol Lab Med 1994;118: 616-618.
115. Angelsen A, Waldum HL, Brenna E. Neuroendocrine differentiation in prostatic carcinoma [letter]. Hum Pathol 1995;26: 1389.
116. Zhau HE, Zhao L-S, Chung LWK, Chen B-Q, Troncoso P, Kao C, Kojima M, Symmans WF, Zheng N, Palmer JL, Moul JW, Davis R, Ye M-F, Xiao LS, Hall MC. Comparative studies of prostate cancers among United States, Chinese, and Japanese patients: characterization of histopathology, tumor angiogenesis, neuroendocrine factors, and p53 protein accumulations. Urol Oncol 1995;1:51-63.
117. Iwamura M, Geshagen S, Lapets O, Moynes R, Abrahamsson PA, Cockett ATK, Deftos LJ, di Sant'Agnese PA. Immunohistochemical localization of parathyroid hormone-related protein in prostatic intraepithelial neoplasia. Hum Pathol 1995;26: 797-801.
118. Nakada SY, di Sant'Agnese PA, Moynes RA, Hiipakka RA, Liao S, Cockett ATK, Abrahamsson PA. The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue. Cancer Res 1993;53:1967-1970.
119. Krijnen JLM, Janssen PJA, Ruizeveld de Winter JA, van Krimpen H, Schröder FH, van der Kwast TH. Do neuroendocrine cells in human prostate cancer express androgen receptor? Histochemistry 1993;100:393-398.
120. Bonkhoff H, Stein U, Remberger K. Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate. Virchows Archiv [A] 1993;423: 291-294.
121. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994;54:5474-5478.
122. Power RF, Mani SK, Codina J, Connely OM, O'Malley BW. Dopaminergic and ligand-independent activation of steroid hormone receptors. Science 1991;254:1636-1639.
123. Bonkhoff H, Stein U, Welter C, Remberger K. Differential expression of the PS2 protein in the human prostate and prostate cancer: association with premalignant changes and neuroendocrine differentiation. Hum Pathol 1995;26:824-828.
124. Julius D, Livelli TJ, Jessell TM, Axel R. Ectopic expression of the serotonin 1c receptor and the triggering of malignant transformation. Science 1989;244:1057-1062.
125. Lowy DR, Willumsen BM. Function and regulation of ras. Annu Rev Biochem 1993;62:851-891.
126. Satoh T, Nakafuka M, Kaziro Y. Function of ras as a molecular switch in signal transduction. J Biol Chem 1992:24149-24152.
127. Hall A. A biochemical function for Ras - at last. Science 1994; 264:1413-1414.
128. Avruch J, Zhang X-F, Kyriakis JM. Raf meets Ras: completing the framework of a signal transduction pathway. Trends Biochem Sci 1994;19:279-283.
129. Allinson ET, Drucker DJ. Parathyroid hormone-like peptide shares features with members of the early response gene family: rapid induction by serum, growth factors, and cycloheximide. Cancer Res 1992;52:884-893.
130. Li X, Drucker DJ. Parathyroid hormone-related peptide is a downstream target for ras and src activation. J Biol Chem 1994; 269:6263-6266.
131. Alsat E, Haziza J, Scippo M-L, Frankenne F, Evain-Brion D. Increase in epidermal growth factor receptor and its mRNA levels by parathyroid hormone (1-34) and parathyroid hormone-related protein (1-34) during differentiation of human trophoblast cell in culture. J Cell Biochem 1993;53:32-42.
132. Kremer R, Karaplis AC, Henderson J, Gilliver W, Banville D, Hendy GN, Goltzman D. Regulation of parathyroid hormone-like peptide in culture normal human keratinocytes: effect of growth factors and 1,25 dihydroxyvitamine D3 on gene expression and secretion. J Clin Invest 1991;87:884-893.
133. Ferrari SL, Rizzoli R, Bonjour JP. Parathyroid hormone-related protein production by primary cultures of mammary epithelial cells. J Cell Physiol 1992;150:304-311.
134. Avis IL, Kovacs TOG, Kasprzyk PG, Treston AM, Bartholomew R, Walsh JH, Cuttitta F, Mulshine JL. Preclinical evaluation of an anti-autocrine growth factor monoclonal antibody for treatment of patients with small-cell lung cancer. JNCI 1991;83:1470-1476.
135. Moody TW, Pert C, Gazdar AF. High levels of intracellular bombesin characterize human small cell lung carcinoma. Science 1981;214:1246-1248.
136. Shimoda J, Koh D, Kigure T, Harada T, Tsuchida S, Kudo K. Effect of bombesin and its antibody on human prostatic carcinoma cell lines (DU-145, PC-3). J Urol 1991;145:400.
137. Bologna M, Festuccia C, Muzi P, Biordi L, Ciomei M. Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer 1989;63:1714-1720.
138. 125I-(Tyr 4) bombesin by tumor cells. Prostate 1994;25:29-38.
139. di Sant'Agnese PA. Calcitonin-like immunoreactive and bombesin-like immunoreactive endocrine-paracrine cells of the human prostate. Arch Pathol Lab Med 1986;110:412-415.
140. Jelbart ME, Russell PJ, Fullerton M, Russell P, Funder J, Raghavan D. Ectopic hormone production by a prostatic small cell carcinoma xenograft line. Mol Cell Endocrinol 1988;55:167-171.
141. Hoosein NM, Logothetis CJ, Chung LWK. Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC-160 on the invasive capacity of human prostatic carcinoma cells. J Urol 1993;149:1209-1213.
142. Rozengurt E, Sinnett-Smith J. Early signals underlying the induction of the c-fos and c-myc genes in quiescent fibroblasts: studies with bombesin and other growth factors. Prog Nucleic Acid Res Mol Biol 1988;35:261-295.
143. Rozengurt E. Neuropeptides as cellular growth factors: role of multiple signalling pathways. Eur J Clin Invest 1991;21:123-134.
144. Steiner MS, Zhou Z-Z, Tonb DC, Barrack ER. Expression of transforming growth factor-β1 in prostate cancer. Endocrinology 1994;135:2240-2247.
145. Latil A, Baron JC, Cussenot O, Fournier G, Boccon-Gibod L, Le Due A, Lidereau R. Oncogene amplifications in early-stage human prostate carcinomas. Int J Cancer 1994;59:637-638.
146. Buttyan R, Sawczuk IS, Benson MC, Siegal JD, Olsson CA. Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers. Prostate 1987;11:327-337.
147. Bussemakers MJG, Isaacs JT, Debruyne FMJ, Van de Ven WJM, Schalken JA. Oncogene expression in prostate cancer. World J Urol 1991;9:58-63.
148. Wynik D, Bloom SR. The use of the long-acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors. J Clin Endocrinol Metab 1991;73:1-3.
149. Öberg K. Biology, diagnosis, an treatment of neuroendocrine tumors of the gastrointestinal tract. Curr Opin Oncol 1994;6: 441-451.
150. Kvols L, Moertel C, O'Connell M, Schutt AJ, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome: evaluation of long-acting somatostatin analogue. N Engl J Med 1986;315: 663-666.
151. Reubi JC. A somatostatin analogue inhibits chondrosarcoma and insulinoma tumour growth. Acta Endocrinol (Copenh) 1985;109:108-114.
152. Schally AV, Redding TW. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer. Proc Natl Acad Sci USA 1987;84:7275-7279.
153. Pinski J, Reile H, Halmos G, Groot K, Schally AV. Inhibitory effects of somatostatin analogue RC-160 and androgen-independent Dunning R-3327-AT-1 rat prostate cancer. Cancer Res 1994;54:169-174.
154. Mahmoud S, Staley J, Bogden A, Moreau JP, Coy D. Bombesin analogues inhibit growth of small cell lung cancer in vitro and in vivo. Cancer Res 1991;51:1798-1802.
155. Cuttitta F, Carney D, Mulshine J, Moody TW, Fedorko J, Fichier A. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature 1985; 316:823-826.
156. Mobley C, Kasprzyk P, Carrasquillo JA, Larson SM, Nakanishi Y, Merchant B. Clinical use of a monoclonal antibody to bombesin-like peptide in patients with lung cancer. Ann NY Acad Sci 1988;547:360-372.
157. 125I-(Tyr 4) bombesin by tumor cells. Prostate 1994;25:29-38.
158. Hoosein NM, Logothetis CJ, Chung LW. Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC-160 on the invasive capacity of human prostatic carcinoma cells. J Urol 1993;149:1209-1213.
159. Abdul M, Anezinis PE, Logothetis CJ, Hoosein NM. Growth inhibition of human prostatic carcinoma cell lines by serotonin antagonists. Anticancer Res 1994;14:1215-1220.